Trastuzumab Dosing and Administration Guidelines for HER2‑Positive Breast Cancer

Loading Dose and Standard Regimens

The National Comprehensive Cancer Network (NCCN) recommends an initial loading dose of 8 mg/kg IV on day 1 followed by 6 mg/kg IV every 3 weeks for most adult patients; an alternative weekly regimen uses a 4 mg/kg IV loading dose then 2 mg/kg IV weekly. 1
The American Society of Clinical Oncology (ASCO) endorses the every‑3‑week schedule (8 mg/kg loading, 6 mg/kg maintenance) as the preferred regimen for the majority of patients. 2
Pharmacokinetic studies show that the every‑3‑week schedule is equivalent to weekly dosing while providing greater convenience for patients. 3

Clinical evidence supports a total adjuvant trastuzumab duration of 1 year (≈52 weeks), encompassing any neoadjuvant and adjuvant cycles administered. 2
For patients who receive neoadjuvant trastuzumab, therapy should be continued after surgery to complete the full 1‑year course. 1

Trastuzumab must not be given concurrently with anthracyclines (e.g., doxorubicin, epirubicin) because of a marked increase in cardiotoxicity risk. 2
The drug should be administered concurrently with taxane‑based chemotherapy (e.g., paclitaxel) to achieve optimal efficacy. 2
When an anthracycline‑containing regimen is used, the anthracycline component should be completed first, and trastuzumab should be started with the subsequent taxane phase. 2
The weekly trastuzumab regimen (4 mg/kg loading, 2 mg/kg weekly) is especially useful when combined with weekly chemotherapy schedules such as weekly paclitaxel. 1

Baseline assessment of left ventricular ejection fraction (LVEF) is required; patients with LVEF < 50 % are contraindicated for trastuzumab initiation. 3
LVEF should be re‑evaluated every 3 months throughout the course of therapy. 3
Trastuzumab must be discontinued if LVEF falls below institutional safety thresholds or if symptomatic heart failure develops. 3

Do not reduce the loading dose based solely on patient age; the standard 8 mg/kg loading dose should be used unless specific contraindications exist. 1
Avoid concurrent administration of trastuzumab with anthracyclines, as cardiotoxicity rates rise from approximately 2–4 % to 16–27 %. 2
Do not omit scheduled cardiac monitoring, because asymptomatic cardiac dysfunction can occur and may necessitate dose interruption or discontinuation. 3
Do not truncate trastuzumab therapy before completing 1 year, as the full duration is required to achieve the maximal disease‑free and overall survival benefit. 2

The American Society of Clinical Oncology recommends a loading dose of 8 mg/kg IV followed by 6 mg/kg IV every 3 weeks, or a loading dose of 4 mg/kg IV followed by 2 mg/kg IV weekly for HER2-positive breast cancer, with a recommended duration of 1 year (52 weeks) for adjuvant treatment 4
For combination therapy, trastuzumab should be administered with a taxane but not concurrently with anthracyclines due to increased risk of cardiotoxicity, as recommended by the European Society for Medical Oncology 4, 5

The National Comprehensive Cancer Network recommends trastuzumab at 8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks for the TCH (docetaxel/carboplatin/trastuzumab) regimen 6, 7
For weekly TCH regimen, trastuzumab is given at 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly, as recommended by the National Comprehensive Cancer Network 6, 7

The American Heart Association recommends assessing cardiac function at baseline and monitoring every 3 months during treatment due to potential cardiotoxicity, with patients having LVEF <50-55% not receiving trastuzumab 8

The European Society for Medical Oncology recommends a treatment duration of 1 year (52 weeks) for adjuvant treatment of early breast cancer 4, 5